InsiderTrades

Form 4 for RGNX REGENXBIO Inc.

Accepted 2024-10-02 00:00:00 ET · period of report 2024-10-01 · accession 0001562180-24-007144 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2024-10-02 2024-10-01 RGNX KARABELAS ARGERIS N Dir M - OptEx $3.76 +10.0K 21.3K +89% +$37.6K
DT 2024-10-02 2024-10-01 RGNX KARABELAS ARGERIS N Dir S - Sale+OE $10.11 -10.0K 11.3K -47% -$101.1K
DT 2024-10-02 2024-10-01 RGNX KARABELAS ARGERIS N Dir M - OptEx $0.00 -10.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-01 M A 10,000 $3.76 21,286 D — —
2 Common Common Stock 2024-10-01 S D 10,000 $10.11 11,286 D — — (F2) This transaction was executed in multiple trades at prices ranging from $10.01 to $10.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3 Derivative Stock Options (Right to Buy) 2024-10-01 M D 10,000 $0.00 0 D $3.76 · — to 2025-05-19 10,000 Common Stock (F3) The previously granted option, representing a right to purchase a total of 40,000 shares, became exercisable as follows: 25% of the shares subject to the option vested on May 19, 2015, and the balance vested equal installments over the next 24 months.